Ascendis Pharma A/S (NASDAQ:ASND) Holdings Trimmed by Cinctive Capital Management LP

Cinctive Capital Management LP lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 41.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,271 shares of the biotechnology company’s stock after selling 8,079 shares during the period. Cinctive Capital Management LP’s holdings in Ascendis Pharma A/S were worth $1,683,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ASND. Signaturefd LLC raised its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Pursue Wealth Partners LLC purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $217,000. Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth approximately $205,000. Rhumbline Advisers boosted its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period. Finally, Algert Global LLC grew its position in Ascendis Pharma A/S by 54.6% during the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 770 shares in the last quarter.

Ascendis Pharma A/S Stock Down 1.6 %

NASDAQ:ASND opened at $131.35 on Wednesday. The company’s 50 day moving average is $131.65 and its 200-day moving average is $132.45. Ascendis Pharma A/S has a 12 month low of $101.43 and a 12 month high of $161.00. The firm has a market cap of $7.97 billion, a price-to-earnings ratio of -16.26 and a beta of 0.67.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Research analysts predict that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ASND shares. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Jefferies Financial Group boosted their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Stifel Nicolaus raised their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.